Caribou Biosciences, Inc. (NASDAQ: CRBU) reported a narrowed net loss for the second quarter of 2026, driven by disciplined cost management and reduced operational expenses. The clinical-stage biopharmaceutical company logged a GAAP net loss of $24.3 million ($0.24 per share) for the three months ended June 30, 2026, compared to a loss of $54.1 million ($0.58 per share) in the corresponding period of 2025.

The quarterly loss of $(0.24) per share beat the analyst consensus estimate of $(0.32) by 25 percent. This represents a 31.43 percent improvement over losses of $(0.35) per share from the same period last year. However, quarterly sales of $1.499 million missed the analyst consensus estimate of $2.279 million by 34.23 percent. Sales decreased 43.79 percent year-over-year from $2.667 million in the prior period.

The improvement in the bottom line was primarily attributable to a sharp decline in operating expenses, which fell to $26.8 million from $50.2 million in Q2 2025. This reduction followed a strategic pipeline prioritization and workforce reduction announced in April 2025. Notably, the prior year’s loss included $21.3 million in non-cash impairment charges, whereas no such charges were recorded in the current quarter.

Financial Performance

Licensing and other third-party revenue decreased to $1.5 million in Q2 2026, down from $2.7 million in Q2 2025. Operating expenses contracted significantly across both primary categories:

• Research and development: Expenses fell to $18.9 million from $27.7 million, driven by decreased external contract manufacturing and research organization activities.
• General and administrative: Costs dropped to $7.9 million from $10.4 million, reflecting lower personnel-related expenses and legal fees.

Balance Sheet and Liquidity

As of June 30, 2026, Caribou held $113.8 million in cash, cash equivalents, and marketable securities, a decrease from $142.8 million at the end of December 2025. Total assets stood at $142.8 million, while total liabilities decreased to $44.7 million from $53.2 million year-end 2025.

Management stated that current liquidity is sufficient to fund operations, including dose expansion for CB-011 and start-up activities for the planned ANTLER-3 pivotal phase 3 trial for vispa-cel, through the end of 2027. The company is exploring options to fully fund the ANTLER-3 trial.

What the Numbers Show

The divergence between the reported net loss and the underlying operational burn rate highlights the impact of non-recurring items on Caribou’s financial trajectory. While the headline net loss improved by nearly 55% year-over-year, the comparison is skewed by the absence of the $21.3 million non-cash impairment charge recorded in Q2 2025. Excluding this one-time item, the operational loss compression was more modest, underscoring that the primary driver of the current quarter’s improved metrics was the successful execution of cost-cutting measures rather than a surge in revenue or operational efficiency gains.

Clinical Updates

Caribou also provided updates on its lead programs presented at the 2026 European Hematology Association (EHA) Annual Meeting:

• Vispa-cel: Long-term follow-up data from the ANTLER phase 1 trial reinforced the therapy’s safety and efficacy in second-line large B cell lymphoma (LBCL). An optimized cohort of 27 patients showed an 82% overall response rate and a 67% complete response rate. The company has aligned with the FDA on the design for the ANTLER-3 pivotal phase 3 trial.
• CB-011: Dose escalation data from the CaMMouflage phase 1 trial demonstrated deep responses in high-risk multiple myeloma patients. A cohort of 12 BCMA-naïve patients treated with the recommended dose for expansion showed a 92% overall response rate and an 83% complete response rate. Initial dose expansion data is expected in H2 2026.

Caribou Biosciences reported longer follow-up data for the ongoing CaMMouflage phase 1 trial of CB-011, an off-the-shelf BCMA-targeted CAR-T cell therapy being evaluated for relapsed or refractory multiple myeloma. A single dose of CB-011 produced deep, durable responses in heavily pretreated, BCMA-naïve patients, with an 83% complete response rate and 91% minimal residual disease negativity. The data also indicated that 50% of patients in complete response or better remained so at 15 months.

The company highlighted a case study of a patient who had previously received an anti-BCMA CAR-T therapy and achieved an early complete response with CB-011, which was ongoing as of the data cutoff. These findings are being presented during an oral presentation at the 2026 European Hematology Association Annual Meeting in Stockholm, Sweden.

Key Trial Data

The CaMMouflage phase 1 trial focuses on high-risk, heavily pretreated patient populations. The reported outcomes include:

Caribou Biosciences expects to report initial dose expansion data for both BCMA-naïve and BCMA-exposed patients in H2 2026. The oral presentation at the EHA Annual Meeting is scheduled for June 14, 2026, at 11:00am CEST.